UNSPSC 51312315: Embramine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular structure C18H22BRNO.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 7BJ3V657VC chemically known as 2-((p-bromo-.alpha.-methyl-.alpha.-phenylbenzyl)oxy)-n,n-dimethylethylamine hydrochloride, but more commonly known as embramine hydrochloride, which bears US NIH Compound Identifier 26365. European Medicines Agency schedules Embramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01870MIG.

UNSPSC 51312315 Embramine hydrochloride is a Commodity code with minimal recent state and local procurement activity directly aligned to it. The three recent opportunities tagged under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution—none of which specifically reference embramine hydrochloride. State and local governments use this code to procure pharmaceutical products, but the recent solicitation record shows activity concentrated in broader pharmaceutical procurement vehicles rather than embramine hydrochloride itself. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance), reflecting the mix of direct procurement and cooperative contracting mechanisms typical of pharmaceutical sourcing at the state and local level.

Recent activity spans Florida, Texas, and Minnesota. Seminole County released an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with deliveries to the Seminole County Community Health Building in Sanford, response deadline July 26, 2026. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026, exploring direct-to-manufacturer prescription programs without a formal evaluation timeline. The Minnesota Department of Administration, acting through MMCAP, released an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline and July 1, 2026, contract effective date, requiring vendors to work through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson). The code shows limited recent solicitation activity specifically tied to embramine hydrochloride and substantial activity instead in related pharmaceutical categories under cooperative and direct purchasing structures.